Risankizumab vs. Fumaric Acid Esters in Plaque Psoriasis Risankizumab vs. Fumaric Acid Esters in Plaque Psoriasis
The head-to-head comparison showed that the monoclonal antibody risankizumab was superior to fumaric acid esters in treating moderate-to-severe plaque psoriasis, and with fewer side-effects.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Study Links Air Pollution to Psoriasis Flares Study Links Air Pollution to Psoriasis Flares
More studies are needed to determine if the results are applicable to other populations and how air pollution might affect psoriasis disease activity, the investigators write.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 25, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

Model May Predict PsA Risk in Patients With Plaque Psoriasis
THURSDAY, Feb. 17, 2022 -- A new nomogram may assess the risk for psoriatic arthritis (PsA) in patients with plaque psoriasis, according to a study published online Jan. 20 in the Frontiers of Immunology. Panpan Liu, from Central South University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2022 Category: Pharmaceuticals Source Type: news

Short-Term Exposure to Air Pollution Linked to Psoriasis Flare
WEDNESDAY, Feb. 16, 2022 -- Short-term exposure to air pollution seems to be associated with psoriasis flare, according to a study published online Feb. 16 in JAMA Dermatology. Francesco Bellinato, M.D., from the University of Verona in Italy, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 16, 2022 Category: Pharmaceuticals Source Type: news

Sleep Disturbance Highly Prevalent in Psoriasis Patients
TUESDAY, Feb. 15, 2022 -- Sleep disturbance is highly prevalent among patients with psoriasis and is associated with pruritus, anxiety, and depression, according to a study published online Jan. 12 in the Journal of the European Academy of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2022 Category: Pharmaceuticals Source Type: news

Psoriasis-related Treatment, Hospitalization Due to COVID-19 Psoriasis-related Treatment, Hospitalization Due to COVID-19
Have systemic treatments for psoriasis been associated with an increased risk of hospitalization or in-hospital mortality due to COVID-19?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 7, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Are Dermatologists Interested in Managing CVD Risk in Psoriasis? Are Dermatologists Interested in Managing CVD Risk in Psoriasis?
The authors of the study see their findings as an early but promising step in finding better models to improve cardiovascular outcomes for patients with psoriatic disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2022 Category: Consumer Health News Tags: Dermatology News Source Type: news

Monthly News Roundup - January 2022
Skyrizi Gains Second Approval to Treat Adults with Psoriatic Arthritis Psoriatic arthritis (PsA) is an inflammatory disease of the skin and joints and impacts approximately 30% of patients with psoriasis. In response, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2022 Category: Pharmaceuticals Source Type: news

Increased Dosing Can Benefit Overweight Patients With Psoriasis Increased Dosing Can Benefit Overweight Patients With Psoriasis
' Weight may have an impact on pharmacokinetics and, therefore, on the clinical outcome of biologic treatment for psoriasis, ' the authors commented.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - January 27, 2022 Category: Rheumatology Tags: Dermatology News Source Type: news

A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - January 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Self - Help Aids Quality of Life for People With Psoriasis
Findings show modest, but significant, benefit from either compassion - based or mindfulness - based self - help (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - January 25, 2022 Category: Psychiatry Tags: Dermatology, Psychiatry, Journal, Source Type: news

Self-Help Aids Quality of Life for People With Psoriasis
TUESDAY, Jan. 25, 2022 -- Self-help based on compassion and mindfulness is acceptable to users and can reduce feelings of shame and improve quality of life for people living with psoriasis, according to a study published online Jan. 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS ...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Risk for Cancer Increased After VTE for Patients With Psoriasis
Standardized incidence ratio was 3.0 during first year of follow - up after VTE and decreased to 1.5 during subsequent years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 24, 2022 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Gynecology, Internal Medicine, Oncology, Journal, Source Type: news

FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis
The approval is the second indication for the anti-interleukin 23 monoclonal antibody after approval for plaque psoriasis was granted in 2019.News Alerts (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 23, 2022 Category: Dermatology Tags: Rheumatology News Alert Source Type: news